Effect Of SMEEDS Formulation Of Glimepiride In Combination With Boswellic Acid Extract In Diabetic Induced Rats To Mimic Diabetic Complications

Abstract

The current study's objective was to examine the impact of Boswellic acid when combined with a novel glimepiride formulation. The impact on fasting blood glucose levels of the commercially available glimepiride formulation, Boswellic acid SMEDDS, and Glimepiride SMEEDS alone and in combination was examined for up to 120 minutes. Control and streptozotocin-induced diabetic rats were measured for body weight, fasting blood glucose level, serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), serum urea nitrogen, uric acid, serum cholesterol, serum triglyceride, and serum total proteins. At end of study, the activity of catalase (CAT), superoxide dismutase (SOD), and malondialdehyde (MDA) levels were assessed in kidney homogenate. By lowering blood glucose, safeguarding renal functions, and maintaining normal morphology, glimepiride and BSE SMEDDS therapy greatly decreased the pathogenic features of T2DN. The management of glycemic control, lipid metabolism, and anti-oxidative and anti-inflammatory capabilities may be related to the mechanism of action for this impact. This suggests that the unique combination being suggested will have a considerable effect on blood glutose levels and help to imitate long-term consequences of diabetes including nephropathy